Journal
ANNUAL REVIEW OF NEUROSCIENCE, VOL 41
Volume 41, Issue -, Pages 323-348Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-neuro-080317-062048
Keywords
gene transfer; cell type specificity; adeno-associated virus; AAV; viral capsid engineering; CREATE; systemic delivery
Categories
Funding
- NIA NIH HHS [R01 AG047664] Funding Source: Medline
- NIH HHS [OT2 OD023848] Funding Source: Medline
- NIMH NIH HHS [F31 MH102913] Funding Source: Medline
- NINDS NIH HHS [DP2 NS087949] Funding Source: Medline
- NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH102913] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG047664] Funding Source: NIH RePORTER
- OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [OT2OD023848] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Recombinant viruses allow for targeted transgene expression in specific cell populations throughout the nervous system. The adeno-associated virus (AAV) is among the most commonly used viruses for neuroscience research. Recombinant AAVs (rAAVs) are highly versatile and can package most cargo composed of desired genes within the capsid's similar to 5-kb carrying capacity. Numerous regulatory elements and intersectional strategies have been validated in rAAVs to enable cell type-specific expression. rAAVs can be delivered to specific neuronal populations or globally throughout the animal. The AAV capsids have natural cell type or tissue tropism and trafficking that can be modified for increased specificity. Here, we describe recently engineered AAV capsids and associated cargo that have extended the utility of AAVs in targeting molecularly defined neurons throughout the nervous system, which will further facilitate neuronal circuit interrogation and discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available